Volume 4, Issue 6, November 2019, Page: 115-118
Myelodysplastic Syndromes Experience of the Laboratory of the Military Hospital Avicenna Marrakech
Mouhib Hanane, Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco
Karrati Ilham, Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco
Hanane Zahir, Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco
Yahyaoui Hicham, Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco
Ait Ameur Mustapha, Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco
Chakour Mohammed, Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco
Received: Oct. 31, 2019;       Accepted: Nov. 23, 2019;       Published: Dec. 13, 2019
DOI: 10.11648/j.ajlm.20190406.16      View  71      Downloads  31
Abstract
MDS are clonal disorders of multipotent or myeloid stem cells. The disease is characterized by inefficient hematopoiesis responsible for peripheral cytopenias and contrasting with a rich marrow. The natural course of this disease is acute myeloid leukemia (AML). This is a retrospective study on the files of patients who had a haematological assessment at the laboratory of the military hospital Avicenna Marrakech between July 2014 and July 2018 for a duration of 4 years. Included in our study were all patients with documented myelodysplasia. The average age of patients is 63.63 years with extremes of 19 years and 89 years; the sex ratio was 1.3 (17 men and 13 women). NFS was abnormal in all patients, 96.66% of whom had anemia. The myelogram was performed in all patients and allowed the diagnosis of MDS in 90% of cases. Our study shows that management needs to be further improved by selecting high-risk MDS patients, potentially candidates for allogeneic hematopoietic stem cell transplantation.
Keywords
Myelodysplasia, Haemogram, Anemia, Thrombocytopenia, Neutropenia-Myelogram, Genetic Mutation
To cite this article
Mouhib Hanane, Karrati Ilham, Hanane Zahir, Yahyaoui Hicham, Ait Ameur Mustapha, Chakour Mohammed, Myelodysplastic Syndromes Experience of the Laboratory of the Military Hospital Avicenna Marrakech, American Journal of Laboratory Medicine. Vol. 4, No. 6, 2019, pp. 115-118. doi: 10.11648/j.ajlm.20190406.16
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Ades L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet 2014; 383: 2239-52.
[2]
Duchmann. M, Fenaux. P, Cluzeau. T. Prise en charge des myélodysplasies. Bull Cancer 2015; 102: 11.
[3]
Heiko. K, Markus. G, Gerber. B. Syndrome myélodysplasique: physiopathologie, diagnostic et traitement. Forum Med Suisse 2013; 13 (27–28): 548–557.
[4]
Fenaux. P, Ades. L. Traitement des syndromes myélodysplasiques. RFL 2009; vol 39: 77-85.
[5]
Fenaux. P, Fontenay L. A. M, Raynaud. S et all. Consensus français sur les syndromes myélodysplasiques et la leucémie myélomonocytaire chronique: diagnostic, classifications, traitement. Hématologie 2015; 21: 28-45.
[6]
Fontenay. M, Kosmider. O, Frisan. E, Ettou. S, Lacombe. C. physiologie des syndromes myélodysplasiques. RFL 2009; 39: 31-37.
[7]
B. Odile, Guy. L, Adoue. D. Syndromes myélodysplasiques de l’adulte. Presse Med. 2007; 36: 481–91.
[8]
Comont T, et al. Prise en charge des syndromes myélodysplasiques en 2019: mise au point. Rev Med Interne (2019).
[9]
Roux C, Roulin L. Généralités sur les syndromes myélodysplasiques: épidémiologie, diagnostic et principes de traitement. Hématologie 2016; 22: 288-296.
[10]
Bottomley SS, Fleming MD. Sideroblastic anemia: diagnosis and management. Hematol Oncol Clin North Am 2014; 28 (4): 653–70.
[11]
Sheqwara J, Alkhatib Y. Sideroblastic anemia secondary to zinc toxicity. Blood 2013; 122 (3): 311.
[12]
Ehsan A, Aziz M. Clinico-haematological characteristics in Pakistani patients of primary myelodysplastic syndrome according to World Health Organization classification. J Coll Physicians Surg Pak. 2010; 20 (4): 232-236.
[13]
AMEL SEBAAA, VIRGINIE ECLACHE-SAUDREAU. Apport de l’hybridation in situ en fluorescence (FISH) pour la détection des anomalies cytogénétiques dans les syndromes myélodysplasiques. RFL - juin 2011.
[14]
SCHANZ J, TÜCHLER H, SOLE F, ET AL. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30: 820–829.
[15]
BEN HASSEN, BEN YOUSSEF Y, ZAIRI M, BEN FRADI W, KHALIF A. Aspects cliniques et cytologiques des 44 cas syndromes myélodysplasiques de novo de l adulte. Tunisie 2011.
[16]
MASSIMO B, MARC M, MAURO N, ET AL. Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation. Leukemia Research. 2005. 29: 33-39.
Browse journals by subject